Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio ... The Herald | HeraldOnline.com (press release) Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on ... Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New ... |
